No Data
No Data
Pharming Group to Participate in September Investor Conferences
Galapagos, XPeng, CorMedix And Other Big Stocks Moving Higher On Monday
Earnings Call: Pharming Group Reports Robust Growth and Pipeline Expansion
Pharming Group NV (PHAR) Q2 2024 Earnings Call Transcript
Oppenheimer Initiates Pharming Group(PHAR.US) With Buy Rating, Announces Target Price $31
Oppenheimer Sticks to Its Buy Rating for Pharming Group (PHAR)
No Data
No Data